Skip to main content

Military Health System

Test of Sitewide Banner

This is a test of the sitewide banner capability. In the case of an emergency, site visitors would be able to visit the news page for addition information.

U.S. Military HIV Research Lends Lessons Learned to COVID-19

Image of Gloved hands working in laboratory. A research coordinator at the Walter Reed Army Institute of Research Clinical Trials Center prepares samples prior to the RV575 research study on Sept. 27, 2022. The U.S. Military HIV Research Program launched the phase 1 study, in October, to evaluate varying doses of the Army's novel ALFQ adjuvant in a candidate HIV vaccine to determine the optimal adjuvant dosage level. Since 1986, the U.S. military has been at the forefront of the battle against HIV. (Photo: Mike Walters, U.S. Army)

The U.S. military has led HIV research since 1986, when it stood up the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research at a time when reports of AIDS diagnoses showed almost twofold year-to-year increases in the United States.

Since then, MHRP has been at the forefront of the battle against HIV, helping to protect the U.S. military and improve global health through research to develop an HIV vaccine, reduce new infections, and advance strategies to induce long-term HIV remission.

In February 2020, the emergence of COVID-19 presented a new historic global public health challenge. Like HIV, it represented a destabilizing force that impacted the world, but existing HIV research data and lessons learned helped spearhead the development of COVID-19 vaccines at a “historic pace,” said U.S. Army Col. (Dr.) Julie Ake, director of the MHRP WRAIR, in Silver Spring, Maryland.

A Top Public Health Challenge Threatening Force Readiness

HIV is a “global destabilizing force impacting partner militaries and challenging public health in strategic geographies,” said Ake.

“HIV continues to threaten global health with 38 million people living with HIV worldwide and approximately 40 million deaths since 1981.”

And despite the development of prevention tools, there were 1.5 million new infections in 2020, as well as “several hundred new HIV infections in U.S. service members annually, which impairs military readiness, imposes a significant cost to military health systems, and threatens blood safety,” she added.

Military Advances in Medicine

Between 2003 and 2006, MHRP led the first-of-its-kind RV144 clinical trial, known as the Thai HIV Vaccine Study.

“It was the first clinical trial to show some efficacy in preventing HIV infection,” said Ake. “Study results showed that a preventive HIV vaccine is possible, and the landmark trial continues to provide scientific direction to help guide vaccine development and testing.”

She explained that the trial results, announced in 2009, paved the way for MHRP to conduct many experimental vaccine studies to help speed the discovery of a more effective vaccine.

“For example, we showed that longer intervals between the primary vaccination series and later doses boost improved immune responses,” she said.

The MHRP is now studying other ways to improve vaccine strength and breadth, she said, including:

  • Novel vaccine platforms
  • Fractional dosing, which involves using a fraction of the standard dose of a regular vaccine to reach more individuals or minimize the side effects of a full dose of vaccine
  • Adjuvants, which are ingredients that can help people receiving a vaccine create a stronger immune response

“This year, we began a Phase 1 trial [which involves testing in humans] in Bangkok, Thailand to evaluate two HIV vaccine candidates,” said Ake. “One is administered with and another without the Army's novel ALFQ [a type of vaccine component called Army liposome formulation with a QS-21 adjuvant] to evaluate adjuvants and boosting strategies for better immune responses. We also began a trial at the WRAIR Clinical Trials Center in Silver Spring to select the optimal dose of the ALFQ adjuvant to use with protein-based vaccines.”

Additionally, Ake said MHRP began its first preclinical animal study of an mRNA HIV vaccine in early 2022. (Preclinical research occurs prior to clinical studies with humans, to find out if a drug or treatment is likely to be useful.)

“The WRAIR’s pilot bioproduction facility is developing the capacity to manufacture mRNA-based HIV vaccines for clinical trials on campus and internationally,” she said. “We think that this technology, along with improved adjuvants, are important for the next generation of HIV vaccine candidates.”

The study is ongoing and expected to wrap up animal activities in early 2023.

Why has an HIV Vaccine Taken so Long?

A vaccine that prevents HIV acquisition with “more than modest efficacy” has not yet been developed, said U.S. Air Force Col. (Dr.) Jessica Cowden, chief of the Department of Retrovirology at the Armed Forces Research Institute of Medical Sciences, in Bangkok, Thailand.

“Much of that is due to the extreme complexity of the virus, its mechanisms of infection, and its pathogenesis, or the process by which disease develops,” said Cowden. “Other factors are related to the global genetic diversity, the lack of animal models, and the changing landscape of prevention strategies which make large efficacy trials increasingly more difficult.”

The virus has many different HIV subtypes and strains circulating around the globe, added Ake.

“Once a person is infected, HIV continues to mutate rapidly. It hides from the immune system, making it very hard to target with a single vaccine,” she said. “The types of immune responses needed for protection are complex, and we continue to improve the strategies to induce these immune responses.”

Laboratory setting
Study samples are displayed in preparation for a research study launched in October 2022 at the Walter Reed Army Institute of Research to evaluate varying doses of an adjuvant for an HIV vaccine candidate. Since 1986, the U.S. military has been at the forefront of the battle against HIV. (Photo: Mike Walters, U.S. Army)

Lessons Learned from COVID-19 Research

The decades-long HIV research science provided valuable lessons for COVID-19 vaccine research.

It was “firmly built on the HIV vaccine research foundation and leveraged the scientific advances and capabilities of decades of HIV research,” said Cowden. It also leveraged extensive research network sites and community engagement teams and strategies, she added.

For example, “monoclonal antibodies were already under development to prevent and treat HIV when COVID-19 emerged,” said Ake.

In addition, experts from the HIV field—including Ake and others at WRAIR—provided technical assistance to federal efforts which came to be known as the Countermeasures Acceleration Group.

“WRAIR’s unique strengths in infectious diseases research, specifically around vaccine development, community engagement, clinical trial design, and immune monitoring laboratory assays, helped guide tremendous efforts to develop and test novel vaccines, diagnostics, and therapeutics,” she said.

For example, she said scientists at WRAIR leveraged expertise developed through the study of HIV and other viruses to design, produce, and test a type of vaccine candidate for COVID-19 called Spike Protein Ferritin Nanoparticle Opens in animal and human trials.

“As the epidemic evolved, WRAIR also contributed knowledge about the ongoing genetic diversity of the virus and the potential impacts of virus variability on the vaccines in use and in development,” she added.

Cowden listed additional contributions of the HIV vaccine research effort to the COVID-19 vaccine development effort. These include:

  • The COVID-19 effort tested vaccine platforms that had already been developed and tested in HIV as well as for other emerging pathogens prior to SARS-CoV-2.
  • Expertise in viral diversity and evolution.
  • Expertise in structure-based vaccine design, immunology, and structural biology.
  • Leveraging global clinical research capacity sites.
  • Applying and utilizing community engagement, education, and participation experience pioneered in HIV research for COVID-19 research.
  • Research collaborations.

Ake explained that MHRP is part of several National Institutes of Health-funded networks, which the COVID-19 effort leveraged with other worldwide collaborators for coronavirus studies.

For example, “MHRP clinical research site partners in Kenya and Uganda played a key role in testing candidate vaccines and therapies, including enrolling over 2,000 participants in COVID vaccine efficacy trials,” she said. And “at the local level, community advisory boards—already in place for HIV vaccine studies—were leveraged for COVID studies to help engage communities.”

Unparalleled COVID-19 Vaccine Development

The success of the COVID-19 vaccine development has also provided valuable insight for HIV research. For example, Ake said work on the mRNA vaccine platform for HIV vaccines is being accelerated because of the success of the mRNA COVID-19 vaccines.

“The speed and global collaboration with which COVID-19 vaccines and treatments were tested and approved was unprecedented,” said Ake. “It shows what is possible,” and provides hope that timelines for HIV vaccine development will become quicker as well.

In addition, “the rapid testing and scalability of mRNA products seen through COVID-19 have increased the acceptability of such an intervention to both prevent and treat diseases,” said Ake, underscoring the importance of strong industry engagement.

Cowden highlighted that the COVID-19 vaccine development effort was “unparalleled in its resourcing,” in terms of human effort and financial investment. It united public, private, and academic entities across sectors to work towards a common purpose, she said.

“There are many lessons from this effort that people hope to harness and apply in the HIV vaccine development effort,” she added.

Some of those include:

  • Using technologies developed for COVID-19 for HIV vaccines.
  • Accelerating development timelines by modeling regulatory pathways from COVID vaccine development efforts (such as clinical development steps done in parallel to improve efficiency and sharing information processes between regulatory bodies).
  • Continuing to build on collaborations between academia, industry, and governments.
  • Harnessing creativity and unity of purpose and decision-making from COVID-19 vaccine development efforts and applying those back in the HIV vaccine development field.

Likewise, “the research community must continue to engage community leaders, key opinion leaders, and community organizations to try to build trust and ensure the concerns and needs of minority and higher risk populations are considered and included in clinical trial design and execution,” concluded Cowden.

For more information on HIV testing and treatments, talk to your health care provider.

You also may be interested in...

How COVID-19 Public Health Emergency’s End Affects TRICARE

Article Around MHS
Immunization Clinic photo

The Public Health Emergency (PHE) for COVID-19 expired at the end of May 11. You might be wondering what this means about the state of COVID-19 or if there are changes to your TRICARE coverage.

Protecting the Warfighter's Health and Readiness, Now and Into the Future

Article Around MHS
An anopheles mosquito specimen sample sits under the microscope during a demonstration of the U.S. Army’s medical technology development and modernization efforts, Fort Detrick, Maryland, on Feb. 23. (Photo by Summer Abdoh, U.S. Army)

A cure for a debilitating and sometimes deadly disease, new treatments for working military dogs, a snakebite antidote, and a treatment for respiratory disease! See how years of research collaborations are providing protections for warfighters in remote places like never before.

COVID-19 Registry Provides Pandemic Response Insights, Optimizes Patient Care

COVID-19 Registry Provides Pandemic Response Insights, Optimizes Patient Care

Prior to the pandemic, the DOD began deploying MHS GENESIS, the new federal electronic health record, to improve health care outcomes for our service members, veterans, and their families. Critical enterprise needs quickly came to light to combat the impacts of the COVID-19 disease.

Navy’s Global Engagement Helps Identify and Mitigate Disease

Navy’s Global Engagement Helps Identify and Mitigate Disease

In support of the Military Health System, the Naval Medical Research Unit-2 is just one global entity that works with local partners to identify and combat global health threats.

Brooke Army Medical Center Interventional Radiology Offers Less-Invasive Option for Patients with Disc Degeneration

Article Around MHS
U.S. Air Force Maj. (Dr.) Matthew Taon, interventional radiologist, demonstrates a minimally invasive image guided procedure at Brooke Army Medical Center, Fort Sam Houston, Texas. (Photo by Jason W. Edwards, Brooke Army Medical Center)

You may not have to go "under the knife" to ease debilitating back issues, thanks to a new technology. Find out how surgeons at Brooke Army Medical Center are relieving patients from pain where surgery was once the only option.

PrEP: Learn About the Highly Effective Drug to Prevent HIV

PrEP: Learn About the Highly Effective Drug to Prevent HIV

HIV pre-exposure prophylaxis drugs, otherwise known as PrEP, are powerful weapons against HIV. Through education and raising awareness of HIV exposures, the risks of getting the disease are lower than ever.

Belvoir Hospital Reaches Milestone with Robotic-Assisted Joint Replacement Surgery

Article Around MHS
Fort Belvoir Community Hospital is the first military hospital in the Defense Health Agency to employ this robotic-assisted platform, and the cutting-edge technology provides the joint replacement surgeons an unparalleled amount of real-time surgical data.  (Photo by Reese Brown, Fort Belvoir Community Hospital)

Would you trust your surgical procedure to a robot? See the cutting-edge technology that's taking Belvoir Hospital's joint replacement surgery into a new era.

USU President Encourages Attendees to “Think Outside the Box” at Infectious Disease Symposium

Article Around MHS
Uniformed Services University President Dr. Jonathan Woodson delivered opening remarks during IDCRP's first annual Science Symposium March 6-10. The event was held in collaboration with the Defense Health Agency Infectious Disease Working Group Subcommittee. (Photo by  HJF communications)

Infectious diseases like COVID-19, HIV, and battlefield wound infections cause illness and disruptions that threaten health and military readiness around the world. To help foster collaboration in the field and share best practices, the Uniformed Services University’s Infectious Disease Clinical Research Program hosted its first Science Symposium March 6-10.

Walter Reed Audiology and Speech Pathology Center Focuses on Improving Quality of Life for Military Health System Beneficiaries

Article Around MHS
World Hearing Day is observed annually on March 3, and this year’s theme is “Ear and Hearing Care for All.”  (Courtesy photo)

Although World Hearing Day is observed just one day during the year, the Audiology and Speech Pathology Center at Walter Reed National Military Medical Center focuses on improving the health and quality of life for MHS beneficiaries nearly every day of the year.

How This USU Student's Daughter Inspired His Surgery Invention

Article Around MHS
U.S. Army 2nd Lt. Harvey Harper and his daughter, Niyah, who was integral to the development of the Harper Innovative Safety Suture Kit. (Photo by U.S. Army 2nd Lt. Harvey Harper)

A surgical tool inspired by a child's toy? The father-daughter collaboration that gave us the Harper Innovative Safety Suture Kit.

Innovations in Military Medicine Recognized by Military Health System

U.S. Army Lt. Gen. Telita Crosland, director of the Defense Health Agency, presents Beverly Luce, senior nurse consultant with DHA’s Primary Care Clinical Management Team, the Federal Military Nursing Leadership Excellence Award. Luce was given the award during the Military Health System awards ceremony at National Harbor, Maryland, on Feb. 16.  

The Military Health System and AMSUS, the society of federal health professionals, presented a series of awards.

Genome Sequencing Work at U.S. Air Force School of Aerospace Medicine

Military personnel posing by Wright-Patterson AFB sign

U.S. Air Force School of Aerospace Medicine technicians and scientists working in Military Health System laboratories helped to identify COVID-19 variants using special sequencing technology.

Vision Center of Excellence Sponsoring Landmark Eye Health Study

Military personnel in eye exam

Eye problems can end military careers. Now, there's new study that could launch a better way to screen and track service members' vision heath. See why expanding the current guidelines for routine eye care can help you.

Brooke Army Medical Center Using New Robotic Guidance System for Spine Surgery

Article Around MHS
Military medical personnel performing spinal surgery

Groundbreaking innovations at Brooke Army Medical Center (BAMC) are taking spinal surgery to a whole new level. Hear from a surgeon and his patient about the incredible benefits of BAMC's new robotic guidance system.

Frontline Expeditionary Dental Care is Near-Time Reality

Article Around MHS
Field Portable Dental System

U.S. Army Medical Materiel Development Activity’s Warfighter Deployed Medical Systems is working to modernize several field deployable dental treatment systems to provide dental treatments to warfighters in a not-so typical way.

Page 1 of 32 , showing items 1 - 15
First < 1 2 3 4 5  ... > Last 
Refine your search
Last Updated: May 02, 2023
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on Twitter Follow us on YouTube Sign up on GovDelivery